Related Experiment Video
Updated: May 1, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
825
Pharmacogenetic considerations for acute lymphoblastic leukemia therapies
Stéphanie Dulucq1, Caroline Laverdière, Daniel Sinnett
1University Health Center Bordeaux, Heamatology Laboratory , Bordeaux , France.
Expert Opinion on Drug Metabolism & Toxicology
|March 29, 2014
Summary
Genetic variations influence treatment outcomes in childhood acute lymphoblastic leukemia (ALL). Understanding these genetic markers can improve drug efficacy and reduce toxicities for better patient survival.
Area of Science:
- Pharmacogenomics
- Pediatric Oncology
- Leukemia Research
Background:
- Childhood acute lymphoblastic leukemia (ALL) treatment has improved survival, but 20% face drug resistance.
- Treatment toxicities are life-threatening and can cause interruptions, impacting long-term health in survivors.
- Patient genetics significantly influence variable treatment outcomes and responses.
Purpose of the Study:
- To review genetic factors affecting treatment response and late effects in childhood ALL.
- To identify common polymorphisms associated with drug efficacy and toxicity.
- To explore the role of patient genetics in ALL treatment variability.
Main Methods:
- Summary of candidate gene and genome-wide association studies (GWAS).
- Identification of genetic variants impacting antileukemic drug effects and leukemic cell biology.
- Inclusion of studies on late treatment effects and pharmacogenetics.
Main Results:
- Identified genetic variants in folate-dependent enzymes, transporters, metabolizing enzymes, and apoptotic proteins.
- Demonstrated the role of common polymorphisms in treatment response variability.
- Highlighted specific genetic markers influencing drug effects and leukemic cell biology.
Conclusions:
- Numerous pharmacogenetic studies have identified potential markers for ALL treatment.
- Further comprehensive insight into genome variations influencing drug responses is necessary.
- Whole exome/genome sequencing and collaborative studies are crucial for personalized ALL treatment and improved outcomes.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:27Pharmacogenetics of Drug Metabolism: Overview
194
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
194